HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial.

AbstractOBJECTIVES:
We aimed to compare the effects of upstream tirofiban versus downstream high-dose bolus (HDB) tirofiban and abciximab on tissue level perfusion and troponin I release in high-risk non-ST-segment elevation acute coronary syndrome (ACS) patients treated with percutaneous coronary intervention (PCI).
BACKGROUND:
Optimal timing and dosage of glycoprotein IIb/IIIa inhibitors for ACS remain to be explored.
METHODS:
We randomized 93 high-risk ACS patients undergoing PCI to receive upstream (in the coronary care unit) tirofiban, downstream (just prior to PCI) HDB tirofiban, and downstream abciximab. We evaluated the effects of the three drug regimens on tissue-level perfusion using the corrected Thrombolysis In Myocardial Infarction (TIMI) frame count, the TIMI myocardial perfusion grade (TMPG), and intracoronary myocardial contrast echocardiography (MCE) before and immediately after PCI and after cardiac troponin I (cTnI).
RESULTS:
The TMPG 0/1 perfusion was significantly less frequent with upstream tirofiban compared with HDB tirofiban and abciximab both before (28.1% vs. 66.7% vs. 71%, respectively; p = 0.0009) and after PCI (6.2% vs. 20% vs. 35.5%, respectively; p = 0.015). Upstream tirofiban was also associated with a significantly higher MCE score index (0.88 +/- 0.18 vs. 0.77 +/- 0.32 vs. 0.71 +/- 0.30, respectively; p < 0.05). Post-procedural cTnI elevation was significantly less frequent among patients in the upstream tirofiban group compared with the HDB tirofiban and abciximab groups (9.4% vs. 30% vs. 38.7%, respectively; p = 0.018). The cTnI levels after PCI were significantly lower with upstream tirofiban compared with HDB tirofiban (3.8 +/- 4.1 vs. 7.2 +/- 12; p = 0.015) and abciximab (3.8 +/- 4.1 vs. 9 +/- 13.8; p = 0.0002)
CONCLUSIONS:
Among high-risk non-ST-segment-elevation ACS patients treated with an early invasive strategy, upstream tirofiban is associated with improved tissue-level perfusion and attenuated myocardial damage.
AuthorsLeonardo Bolognese, Giovanni Falsini, Francesco Liistro, Paolo Angioli, Kenneth Ducci, Tamara Taddei, Roberto Tarducci, Franco Cosmi, Silvia Baldassarre, Antonio Burali
JournalJournal of the American College of Cardiology (J Am Coll Cardiol) Vol. 47 Issue 3 Pg. 522-8 (Feb 07 2006) ISSN: 1558-3597 [Electronic] United States
PMID16458130 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • Immunoglobulin Fab Fragments
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Troponin I
  • Tyrosine
  • Tirofiban
  • Abciximab
Topics
  • Abciximab
  • Angioplasty, Balloon, Coronary
  • Antibodies, Monoclonal (administration & dosage)
  • Coronary Circulation
  • Coronary Disease (drug therapy, physiopathology, therapy)
  • Echocardiography
  • Electrocardiography
  • Humans
  • Immunoglobulin Fab Fragments (administration & dosage)
  • Platelet Aggregation Inhibitors (administration & dosage)
  • Platelet Glycoprotein GPIIb-IIIa Complex (antagonists & inhibitors)
  • Risk Factors
  • Tirofiban
  • Troponin I (blood)
  • Tyrosine (administration & dosage, analogs & derivatives)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: